Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice

Lapierre, Valérie; Kuentz, M; Tiberghien, Pierre

doi:10.1038/sj.bmt.1702203

Cited by 37 publications

(22 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…125 The reports of hemolysis involving non-ABO red cell antigens emphasize the importance of screening both donor and recipient for the presence of other antibodies and providing appropriate blood component support before and after transplantation. Further investigation of positive antibody screens for either the donor or recipient should be performed to determine donor-patient red cell compatibility before transplantation, and patient records reviewed for a history of red cell antibodies.…”

Section: Transfusion Support For Red Cell-incompatible Transplantationmentioning

confidence: 99%

“…135 The Societe Francaise de Greffe de Moelle realized the existing heterogeneity of transfusion practices and recognized the importance of standard management techniques for patients enrolled into a clinical study comparing PBPC and marrow transplantation. 125 For this study, patients and donors underwent comprehensive phenotyping of red cell antigens including Rh, Kell and Lewis, and required transfusion support with red cells compatible to both donor and recipient beginning at day 0, and earlier if possible. Post-transplant identification and titration of isoagglutinins was also required.…”

Section: Transplant Program Standardsmentioning

confidence: 99%

See 1 more Smart Citation

Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation

Rowley

Donato

Bhattacharyya

2011

Bone Marrow Transplant

121

104

View full text Add to dashboard Cite

Section: Transfusion Support For Red Cell-incompatible Transplantationmentioning

confidence: 99%

Section: Transplant Program Standardsmentioning

confidence: 99%

Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation

Rowley

Donato

Bhattacharyya

2011

Bone Marrow Transplant

121

104

View full text Add to dashboard Cite

“…There are few data to support the safety and efficacy of current practices. 11 What data exist primarily come instead from the setting of randomized trials in patients undergoing induction therapy for acute leukemia, and some observational studies in stem cell transplantation. Most of these studies do not follow patients longitudinally through consolidation and transplant therapy to determine if transfusion practices alter clinical outcomes.…”

Section: Transfusionmentioning

confidence: 99%

What would Karl Landsteiner do? The ABO blood group and stem cell transplantation

Heal

Liesveld

Phillips

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:ABO blood group antigens, of great importance in transplantation and transfusion, are present on virtually all cells, as well as in soluble form in plasma and body fluids. Naturally occurring plasma IgM and IgG antibodies against these antigens are ubiquitous. Nonetheless, the ABO blood group system is widely ignored by many transfusion services, except for purposes of red cell transfusion. We implemented a policy of transfusing only ABO identical platelets and red cells in patients undergoing stem cell transplantation or treatment for hematologic malignancies. Major bleeding episodes have occurred in about 5% of patients undergoing induction therapy for acute leukemia as compared with 15-20% in the literature. Overall survival times appear to be superior to that in historical cohorts. In 2002-2004, treatment-related mortality at 100 days in our Blood and Marrow Transplant Unit was 0.7% for autologous transplants (n ¼ 148), 13% for sibling allogeneic transplants (n ¼ 110), and 24% (n ¼ 62) for matched unrelated allogeneic transplants, suggesting that our approach is safe. We speculate that more rigorous efforts on the part of transfusion services to provide ABO identical blood components, and to remove incompatible supernatant plasma, when necessary, might yield reduced morbidity and mortality in patients undergoing stem cell transplantation. Bone Marrow Transplantation (2005) 36, 747-755.

show abstract

“…Published guidelines for post-HSCT transfusion are applicable to post-HSCT pregnancy-related transfusion needs, and the use of irradiated blood products may be prudent. 16,17 However, for HDN, previous pre-HSCT pregnancy history cannot predict the risk. This is because both the red cell and immune system of the pregnant HSCT recipient have switched to that of host origin.…”

Section: Hematological Testsmentioning

confidence: 99%

Challenges and pitfalls in prenatal screening in pregnancies involving allogeneic stem cell transplantation recipients

Leung

2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Increasing numbers of successful pregnancies are reported in recipients of allogeneic hemopoietic stem cell transplantation (HSCT). These may occur naturally, or more commonly, through assisted reproduction. The pregnancy outcomes are usually normal. There are currently no guidelines on the prenatal management of pregnancies involving HSCT recipients. HSCT recipients are unique in that their red cells, lymphocytes and even the DNA in the circulation are donor derived. As a result, typical prenatal screening tests in parents, including mean cell volume (MCV), hemoglobin pattern, blood group, infective serology and DNA screening, are all affected. The MCV cannot be used as guide for iron and folate supplements, or for thalassemia and sickle cell anemia screening. Such screening must be based on pre-HSCT indices and pre-HSCT DNA samples. The risks for hemolytic disease of newborn and hepatitis B virus transmission have to be re-evaluated, based on both preand post-HSCT patient as well as donor blood group and serology results. Good communication between obstetricians and the HSCT physician is paramount to promote successful pregnancies in this distinct patient population.

show abstract

Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice

Cited by 37 publications

References 28 publications

Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation

Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation

What would Karl Landsteiner do? The ABO blood group and stem cell transplantation

Challenges and pitfalls in prenatal screening in pregnancies involving allogeneic stem cell transplantation recipients

Contact Info

Product

Resources

About